The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2019 Oct 19

PMID 31623191

Citations 10

Authors

Gi Hyue Park

Seungyeon Kim

Min Soo Kim

Yun Mi Yu

Gun Hee Kim

Jeong Sang Lee

Euni Lee

Affiliations

Soon will be listed here.

Abstract

Cephalosporins that contain the N-methylthiotetrazole side chain (NMTT-cephalosporin) have been reported to be associated with coagulation-related adverse events; however, a comprehensive evaluation regarding the association is lacking. A systematic review and meta-analysis were conducted to assess the safety profile of NMTT-cephalosporins with respect to hypoprothrombinemia and bleeding. The MEDLINE, Embase, Cochrane, and RISS databases were systematically searched for clinical studies up to October 2018. The association between NMTT-cephalosporins and hypoprothrombinemia was estimated using an odds ratio (OR) with a 95% confidence interval (CI). A total of 15 studies on cefamandole, cefoperazone, cefotetan, cefmetazole, and moxalactam were identified and included in the meta-analysis. Hypoprothrombinemia (OR 1.676, 95% CI 1.275-2.203) and prothrombin time (PT) prolongation (OR 2.050, 95% CI 1.398-3.005) were significantly associated with NMTT-cephalosporins, whereas bleeding was not (OR 1.359, 95% CI 0.920-2.009). Subgroup analyses revealed that cefoperazone (OR 2.506, 95% CI 1.293-4.860), cefamandole (OR 3.247, 95% CI 1.083-9.733), and moxalactam (OR 3.367, 95% CI 1.725-6.572) were significantly associated with hypoprothrombinemia. An Antimicrobial Stewardship Program led by a multidisciplinary team could play a critical role in monitoring cephalosporin-related hypoprothrombinemia or PT prolongation in patients with underlying clinical conditions at risk for bleeding. The multidisciplinary team could also assist in communicating the potential safety concerns regarding NMTT-cephalosporin use with healthcare professionals to decrease the risk of adverse events.

Citing Articles

Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses.

Ebid A, Abdeen H, Muhammed Maher R, Mohamed-Abdel-Motaleb S Hosp Pharm. 2024; 59(5):575-583.

PMID: 39318741 PMC: 11418688. DOI: 10.1177/00185787241238310.

A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation.

Liu J, Xiao J, Wu H, Ye J, Li Y, Zou B Int J Clin Pharm. 2024; 46(6):1492-1499.

PMID: 39269640 DOI: 10.1007/s11096-024-01796-w.

Estimation of latamoxef (moxalactam) dosage regimens against β-lactamase-producing Enterobacterales in dogs: a pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulation.

Kusumoto M, Narita H, Motegi T, Harada K J Vet Med Sci. 2024; 86(8):841-846.

PMID: 38897952 PMC: 11300127. DOI: 10.1292/jvms.24-0197.

Latamoxef dosing regimen adjustments and pharmaceutical care in pediatrics.

Zhang A, Zuo M, Sun Y, Chen J, Zhu L, Liu W Front Pediatr. 2024; 12:1302087.

PMID: 38362000 PMC: 10867160. DOI: 10.3389/fped.2024.1302087.

Urinary tract dilation classification system for predicting surgical management and urinary tract infection in neonates and young infants: a systematic review and meta-analysis.

Kim H, Hwang J, Pai K, Suh Y Pediatr Radiol. 2024; 54(5):795-804.

PMID: 38282063 DOI: 10.1007/s00247-024-05854-3.

References

Calandra G, Hesney M, Grad C . A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol. 1984; 3(5):478-87. DOI: 10.1007/BF02017380. View

Meyers B . Comparative toxicities of third-generation cephalosporins. Am J Med. 1985; 79(2A):96-103. DOI: 10.1016/0002-9343(85)90268-2. View

Shevchuk Y, Conly J . Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966-1988. Rev Infect Dis. 1990; 12(6):1109-26. View

Yangco B, Baird I, Lorber B, Noble R, Bermudez R, SILVERBLATT F . Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients. J Antimicrob Chemother. 1987; 19(2):239-48. DOI: 10.1093/jac/19.2.239. View

Hu H . Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report. Drug Saf Case Rep. 2019; 6(1):6. PMC: 6570729. DOI: 10.1007/s40800-019-0100-0. View

Nakano E, Fukuoka T, Takeuchi N, Seki T, Tamai M, Araki M . A Case of Alveolar Bleeding from Clotting Abnormality by Cefmetazole. Case Rep Med. 2019; 2019:3574064. PMC: 6360626. DOI: 10.1155/2019/3574064. View

Shearer M, Bechtold H, Andrassy K, Koderisch J, McCarthy P, Trenk D . Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol. 1988; 28(1):88-95. DOI: 10.1002/j.1552-4604.1988.tb03106.x. View

Chen L, Hsiao F, Shen L, Wu F, Tsay W, Hung C . Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study. PLoS One. 2016; 11(7):e0158407. PMC: 4963104. DOI: 10.1371/journal.pone.0158407. View

Williams K, Bax R, Brown H, Machin S . Antibiotic treatment and associated prolonged prothrombin time. J Clin Pathol. 1991; 44(9):738-41. PMC: 496719. DOI: 10.1136/jcp.44.9.738. View

10.

Brown R, Klar J, Lemeshow S, TERES D, Pastides H, Sands M . Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986; 146(11):2159-64. View

11.

Grasela Jr T, Walawander C, Welage L, Wing P, Scarafoni D, Caldwell J . Prospective surveillance of antibiotic-associated coagulopathy in 970 patients. Pharmacotherapy. 1989; 9(3):158-64. DOI: 10.1002/j.1875-9114.1989.tb04122.x. View

12.

Goss T, Walawander C, Grasela Jr T, Meisel S, kATONA B, Jaynes K . Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patients. Pharmacotherapy. 1992; 12(4):283-91. View

13.

Welage L, Hejmanowski L, Wilton J, Walawander C, RIGAN D, Williams J . Comparison of N-methylthiotetrazole dispositions in healthy volunteers following single intravenous doses of moxalactam, cefoperazone, and cefotetan. Antimicrob Agents Chemother. 1989; 33(6):857-61. PMC: 284245. DOI: 10.1128/AAC.33.6.857. View

14.

Huizinga W, Baker L, Kadwa H, van den Ende J, Francis A, FRANCIS G . Management of severe intra-abdominal sepsis: single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. Br J Surg. 1988; 75(11):1134-8. DOI: 10.1002/bjs.1800751126. View

15.

Bertino Jr J, Kozak A, Reese R, Chiarello L . Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital. Arch Intern Med. 1986; 146(6):1125-8. View

16.

Angaran D, Dias V, Arom K, Northrup W, Kersten T, LINDSAY W . The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Cefamandole, cefazolin, vancomycin. Ann Surg. 1987; 206(2):155-61. PMC: 1493101. DOI: 10.1097/00000658-198708000-00007. View

17.

Cohen H, Scott S, Mackie I, Shearer M, Bax R, Karran S . The development of hypoprothrombinaemia following antibiotic therapy in malnourished patients with low serum vitamin K1 levels. Br J Haematol. 1988; 68(1):63-6. DOI: 10.1111/j.1365-2141.1988.tb04180.x. View

18.

Wold J, Buening M, Hanasono G . Latamoxef-associated hypoprothrombinaemia. Lancet. 1983; 2(8346):408. DOI: 10.1016/s0140-6736(83)90381-1. View

19.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

20.

Jones P, Strother S, Rolston K, Fainstein V, Bodey G . Hypoprothrombinemia in patients with cancer receiving cefoperazone and mezlocillin. Arch Intern Med. 1986; 146(7):1397-9. View